After surgical removal of the prostate to treat prostate cancer, clinicians monitor prostate specific antigen (PSA) levels. Persistently elevated PSA levels indicate residual cancer and are linked to ...

After surgical removal of the prostate to treat prostate cancer, clinicians monitor Prostate Specific Antigen (PSA) levels. Persistently elevated PSA levels indicate residual cancer and are linked to ...

Among men with PSA persistence after radical prostatectomy, a higher preoperative PSA surprisingly was linked to lower mortality. Men with PSA persistence and preoperative PSA >20 ng/mL had 31% lower ...

Higher persistent PSA levels post-surgery were linked to increased mortality risk, with 8-year prostate cancer–specific mortality reaching 13.86% for a prostate-specific antigen (PSA) ≥ 1 ng/mL. The ...

Researchers identified three biomarkers that robustly detected the presence of prostate cancer Prostate biopsies after abnormal PSA blood test results are often negative and can result in unintended ...

Prostate cancer is one of the most common cancers that occur in men. While it can be life-threatening, the disease is treatable, and the earlier it is detected, the better the treatment outcome.

A 65-year-old male patient initially presented with a PSA of 10 ng/mL. A 65-year-old male patient initially presented with a PSA of 10 ng/mL. He ultimately underwent a prostate needle biopsy, with 3 ...

A new study led by UCLA Health Jonsson Comprehensive Cancer Center investigators suggests that adding hormone therapy to postoperative radiotherapy may provide little survival benefit for most men ...

A negative scan does not always mean recurrent prostate cancer is nowhere to be found. Sometimes, the disease may simply be too small or too faint to appear yet.

After surgical removal of the prostate to treat prostate cancer, clinicians monitor Prostate Specific Antigen (PSA) levels. Persistently elevated PSA levels indicate residual cancer and are linked to ...

A new study led by UCLA Health Jonsson Comprehensive Cancer Center investigators suggests that adding hormone therapy to post-operative radiotherapy may provide little survival benefit for most men ...